
New and Future Developments in Microbial Biotechnology and Bioengineering
Recent Advances in Application of Fungi and Fungal Metabolites: Applications in Healthcare
- 1st Edition - August 19, 2020
- Imprint: Elsevier
- Editors: Joginder Singh Panwar, Praveen Gehlot
- Language: English
- Hardback ISBN:9 7 8 - 0 - 1 2 - 8 2 1 0 0 6 - 2
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 2 2 5 5 5 - 4
New and Future Developments in Microbial Biotechnology and Bioengineering: Recent Advances in Application of Fungi and Fungal Metabolites: Applications in Healthcare prese… Read more

Purchase options

Institutional subscription on ScienceDirect
Request a sales quoteNew and Future Developments in Microbial Biotechnology and Bioengineering: Recent Advances in Application of Fungi and Fungal Metabolites: Applications in Healthcare presents an account of recent development and applied aspects of fungi and its metabolites in the healthcare sector. Chapters are written by eminent researchers, emphasizing the incredible role of fungi and its metabolites in the field of medicine. This book offers reference material to all mycologists working on the exploration and usage of medicinal aspects of fungi and fungal metabolites.
- Introduces the aspects and advances of fungi and fungal metabolites in healthcare
- Includes a description of traditional uses and modern practices on how to harness the potential of fungi and its metabolites in healthcare applications
- Provides details surrounding the use of fungi and its metabolites in medical purposes
- Describes potential manifold prospects of fungi and fungal metabolites
Learn
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Chapter 1: Prospective of macrofungal metabolites in human health
- Abstract
- 1.1: Introduction
- 1.2: Medicinal mushrooms
- 1.3: Mushroom metabolites
- 1.4: Mechanism of action
- 1.5: Medicinal applications
- 1.6: Conclusions
- Chapter 2: Toxins from Fusarium species and their role in animal and plant diseases
- Abstract
- 2.1: Introduction
- 2.2: Avenacein Y
- 2.3: Beauvericin
- 2.4: Butenolide
- 2.5: Calonectrin
- 2.6: Deoxynivalenol
- 2.7: Diacetoxyscirpenol
- 2.8: Enniatins
- 2.9: Fructigenin
- 2.10: Fumonisin B1
- 2.11: Fusaric acid
- 2.12: Fusarin
- 2.13: HT-2 toxin
- 2.14: Ipomeanine
- 2.15: Lycomarasmin
- 2.16: Moniliformin
- 2.17: Neosolaniol
- 2.18: Nivalenol
- 2.19: Sambucynin (sambucinin)
- 2.20: T-1 toxin (NT-1) and NT-2 toxin
- 2.21: T-2 toxin
- 2.22: Yavanicin (Javanicin)
- 2.23: Zearalenone
- 2.24: Conclusion and future prospects
- Chapter 3: Keratinophilic fungi: Isolation, identification, pathogenicity, characterization, and treatment
- Abstract
- 3.1: Introduction
- 3.2: Sampling techniques for keratinophilic fungi
- 3.3: Ecology of keratinophilic fungi
- 3.4: Identification of keratinophilic fungi
- 3.5: Nutritional requirements of keratinophilic fungi
- 3.6: Growth characteristics of keratinophilic fungi
- 3.7: Effect of environmental factors on keratinophilic fungi
- 3.8: Infection and transmission
- 3.9: Treatment of infections caused by keratinophilic fungi
- 3.10: Antikeratinophilic activity of bioactive compounds from plants
- Chapter 4: Endophytic fungi: A new hope for drug discovery
- Abstract
- 4.1: Introduction
- 4.2: History
- 4.3: Classification of endophytes
- 4.4: Endophytes promote the accumulation of bioactive compounds
- 4.5: The need for endophytes
- 4.6: Process of drug discovery from endophytes
- 4.7: Cultivation and extraction of endophytic fungi
- 4.8: Biopharmaceuticals from endophytes
- 4.9: Conclusion
- Chapter 5: Therapeutic potency of bioactive compounds from fungal endophytes
- Abstract
- Acknowledgments
- 5.1: Introduction
- 5.2: Endophyte-host relationship
- 5.3: Classification of endophytic fungal metabolites based on their bioactivities
- 5.4: Conclusion
- Chapter 6: Role of fungi in neurodegenerative diseases
- Abstract
- 6.1: Introduction
- 6.2: Role of fungus in neurological disease
- 6.3: Treatment of neurodegenerative diseases by nanoformulation of natural compounds
- 6.4: Conclusion and future perspectives
- Chapter 7: Fungal secondary metabolites: A potential source of anticancer compounds
- Abstract
- 7.1: Introduction
- 7.2: Cancer statistics
- 7.3: Oyster mushroom
- Chapter 8: A promising source of anticancer drug from fungal secondary metabolite
- Abstract
- 8.1: Introduction
- 8.2: Fungal metabolites as anticancer agents
- 8.3: Endophytic fungi as a source of anticancer agents
- 8.4: Anticancer agents from endophytic fungi
- 8.5: Current challenges and future prospective
- Chapter 9: Neoteric research trends in marine fungi as promising and alternate sources of anticancer phytochemicals
- Abstract
- Acknowledgment
- Conflict of interest
- 9.1: Introduction
- 9.2: Methodology
- 9.3: Secondary metabolites obtained from marine endophytic fungi associated with mangrove plants
- 9.4: Secondary metabolites obtained from algae-associated marine fungi
- 9.5: Secondary metabolites obtained from sponge-associated marine fungi
- 9.6: Secondary metabolites isolated from marine sediment-derived fungi
- 9.7: Secondary metabolites from marine fungi originating in deep-sea sediment
- 9.8: Metabolites isolated from other types of fungi associated with different organisms or collected from mud or water samples
- 9.9: Discussion
- 9.10: Conclusion
- Chapter 10: Fungal enzyme inhibitors: Repository of novel cancer therapeutics
- Abstract
- 10.1: Introduction
- 10.2: Fungi as a source of anticancer agents
- 10.3: Potential applications of fungal enzyme inhibitors in the management of cancer
- 10.4: Fungal metabolites in cancer clinical trials
- 10.5: Synthetic analogues of fungal metabolites in cancer trials
- 10.6: Fungal metabolites evaluated in vivo in animal models of human cancer
- 10.7: Conclusion
- Chapter 11: Biotechnological approaches for the enhancement of anticancer secondary metabolite production from endophytic fungi
- Abstract
- 11.1: Introduction
- 11.2: Sources of anticancer compounds
- 11.3: Biosynthesis of anticancer metabolites
- 11.4: Improving secondary metabolite production in fungal cell cultures
- 11.5: Conclusion
- Chapter 12: Fungal metabolites—A potential source of antiviral compounds
- Abstract
- 12.1: Introduction
- 12.2: Fungi as a source of antiviral therapeutic agents
- 12.3: Classes of antiviral metabolites
- 12.4: Mechanisms of action of antiviral fungal metabolites
- 12.5: Fungal metabolites against human and animal viruses
- 12.6: Fungal metabolites against plant viruses
- 12.7: Conclusions and future perspectives
- Chapter 13: Chitin: Promising biopolymer for biomedical application
- Abstract
- Acknowledgment
- 13.1: Introduction
- 13.2: Chemical structure of chitin
- 13.3: Chitin sources
- 13.4: Commercial production of chitin
- 13.5: Derivatives of chitin
- 13.6: Properties of chitin
- 13.7: Applications of chitin polymer
- 13.8: Conclusion
- Chapter 14: Antipathogenic activity of fungal secondary metabolites with special reference to human pathogenic bacteria
- Abstract
- 14.1: Introduction
- 14.2: Biosynthesis mechanisms of fungal secondary metabolites
- 14.3: Fungal secondary metabolites in pharmaceutical industries
- 14.4: Fungal secondary metabolites in cosmeceutical industries
- 14.5: Fungal secondary metabolites in skin aging
- 14.6: Fungal metabolites for skin whitening
- 14.7: Fungal metabolites for acne treatments
- Chapter 15: Hypoglycemic potential of mushroom and their metabolites
- Abstract
- 15.1: Introduction
- 15.2: Diabetes and their pathophysiology
- 15.3: Mushrooms as hypoglycemic agents
- 15.4: Conclusions and future scope
- Chapter 16: Biomedical applications of 4-hydroxycoumarin as a fungal metabolite and its derivatives
- Abstract
- 16.1: Introduction
- 16.2: Anticancer activity
- 16.3: Antibacterial potential of 4HC-based derivatives
- 16.4: Anti-HIV capabilities
- 16.5: Antioxidant properties
- 16.6: Anticoagulant properties of 4HC-based compounds
- 16.7: Conclusion
- Chapter 17: Recombinant Pichia pastoris and its applications in healthcare industry
- Abstract
- 17.1: Introduction
- 17.2: Pichia pastoris like an expression system
- 17.3: Pichia pastoris
- 17.4: Healthcare industry
- 17.5: Strategies to improve recombinant subunit vaccine production
- 17.6: Pichia pastoris on human growth hormone
- 17.7: Advantages
- 17.8: Drawbacks
- 17.9: Insulin production for diabetes
- 17.10: Recombinant protein subunit vaccines
- 17.11: The custom of Pichia pastoris in recombinant subunit vaccine development
- 17.12: Evaluation of the existing functional annotation
- 17.13: Recombinant protein subunit vaccines prepared from Pichia pastoris
- 17.14: Epstein-Barr infection vaccine
- 17.15: Dengue infection vaccine
- 17.16: Pichia pastoris for human cell biology (peroxisome biosynthesis) and diseases
- 17.17: Use of Pichia pastoris for the diagnosis of allergic diseases
- 17.18: Future perspectives
- Index
- Edition: 1
- Published: August 19, 2020
- Imprint: Elsevier
- No. of pages: 232
- Language: English
- Hardback ISBN: 9780128210062
- eBook ISBN: 9780128225554
JP
Joginder Singh Panwar
Prof. Joginder Singh is a Professor at the Department of Botany, Nagaland University, Lumami, Nagaland, India. Previously, he worked as a Professor in the School of Bioengineering and Biosciences, Lovely Professional University and also as a Young Scientist at Microbial Biotechnology and Biofertilizer Laboratory, Department of Botany, Jai Narain Vyas University on a research project funded by the Department of Science and Technology, Government of India. He is an active member of various scientific societies and organizations, including the Association of Microbiologists of India, the Indian Society of Salinity Research Scientists, the Indian Society for Radiation Biology, and the European Federation of Biotechnology. He has published extensively with Elsevier and Springer both in journals and books. He serves as a reviewer for many prestigious journals, including Current Research in Engineering, Science and Technology; Journal of Cleaner Production; Science of the Total Environment; Environmental Monitoring and Assessment; Pedosphere; Soil and Sediment Contamination; Symbiosis; International Journal of Phytoremediation; Ecotoxicology and Environmental Safety; Annals of Agricultural Sciences; and Annals of the Brazilian Academy of Sciences.
Affiliations and expertise
Professor, Department of Botany, Nagaland University, Nagaland, IndiaPG
Praveen Gehlot
Dr. Praveen Gehlot is Associate Professor, Department of Botany, Jai Narain Vyas University Jodhpur. He did his PhD from JNV University Jodhpur, under the able guidance of Prof. D.K. Purohit. He has about 18 years of teaching and research experience. He has been an awardee of Young Scientist under FAST Track Scheme by Department of Science and Technology, New Delhi and later worked as a Pool-Officer of Council of Scientific and Industrial Research, New Delhi. Earlier, he taught at Budha Institute of Technology and Science Research College, Jodhpur and Government Bangor PG College, Pali, Rajasthan and subsequently served as an Associate Professor and Head, Department of Microbiology, Maharaja Ganga Singh University, Bikaner, Rajasthan. Dr. Gehlot worked out three major research projects sponsored by UGC, DST and CSIR, New Delhi. He has published more than 80 research papers, book chapters and review articles in journals of international and national repute and has edited three book entitled “Pyrenomycetes Fungi”, “Arbuscular Mycorrhizal Fungi” and “Microbes: In Action” published by AgroBios, India and “Fungi and their Role in Sustainable Development: Current Perspectives” published by Springer International. He attended several International and National Seminars, Symposia, Conferences and chaired technical sessions and presented papers in some of them. He is an active member Mycological Society of India, Society of Mycology and Plant Pathology, India, Association of Microbiologists of India, Indian Science Congress Association, etc.
Affiliations and expertise
Associate Professor, Department of Botany, Jai Narain Vyas University Jodhpur, IndiaRead New and Future Developments in Microbial Biotechnology and Bioengineering on ScienceDirect